Table 4. Hazard Ratios and Median Overall and Progression-Free Survival by Mutation Status.
| Overall survival |
Progression-free survival |
|||||
|---|---|---|---|---|---|---|
| N studies | HR (95% CI) | P-Het; I2 | N studies | HR (95% CI) | P-Het; I2 | |
| Survival analysis (mutant vs. wild-type) | ||||||
| KRAS | 47 | 1.49 (1.37 - 1.64) | < 0.001; 50.2% | 25 | 1.62 (1.33 - 1.97) | < 0.001; 83.1% |
| BRAF | 32 | 2.83 (2.23 - 3.58) | < 0.001; 84.1% | 12 | 2.90 (1.84 - 4.56) | < 0.001; 91.3% |
| NRAS | 4 | 1.88 (1.35 - 2.62) | 0.795; 0.0% | * | * | * |
| Median survival | Median months (95% CI) | Median months (95% CI) | ||||
| KRAS mutant | 41 | 13.41 (11.35 - 15.83) | < 0.001; 96.8% | 42 | 4.48 (3.58 - 5.62) | < 0.001; 99.2% |
| KRAS wild-type | 42 | 17.00 (14.52 - 19.89) | < 0.001; 96.8% | 49 | 5.98 (4.74 - 7.54) | < 0.001; 99.3% |
| P value for difference | 0.022 | 0.04 | ||||
| BRAF mutant | 12 | 8.71 (6.54 - 11.59) | < 0.001; 90.1% | 11 | 5.05 (3.67 - 6.96) | < 0.001; 88.6% |
| BRAF wild-type | 13 | 17.19 (13.00 - 22.74) | < 0.001; 96.6% | 12 | 8.26 (6.78 - 10.07) | < 0.001; 93.5% |
| P value for difference | < 0.001 | 0.005 | ||||
*N < 3 (studies), insufficient for meta-analysis. mCRC: metastatic colorectal cancer; HR: hazard ratio; CI: confidence interval.